Status:

UNKNOWN

Role of Ultrasound Assessment of Parasternal Intercostal Muscle Thickness During Weaning From Mechanical Ventilation

Lead Sponsor:

Wesameldin Abelrahman Soltan

Conditions:

Parasternal Intercostal Muscle Thickness

Weaning From Mechanical Ventilation

Eligibility:

All Genders

18-80 years

Brief Summary

Assessment of the the parasternal intercostal muscles thickness by the ultrasonography as a weaning predictor of the mechanically ventilated patients

Detailed Description

impact of parasternal muscle thickness on the weaning process of the mechanically ventilated patients in ICU

Eligibility Criteria

Inclusion

  • Any patient invasively mechanically ventilated at least 24 hours on a pressure support mode who is clinically stable and ready to undergo a spontaneous breathing trial.
  • All patients will be:
  • Alert.
  • Afebrile.
  • Adequate cough with absence of excessive tracheobronchial secretion.
  • Fraction of inspired oxygen (FIO2) of \<50%.
  • PEEP ≤8 cmH2O.
  • PaO2/FiO2 \> 150.
  • pH ≥7.35 and ≤7.45.
  • Respiratory rate (RR) ≤35 breaths/min.
  • Hemodynamically stable in the absence of vasopressors.
  • Stable metabolic and endocrinal status.
  • Euglycemic state.
  • Adequate mentation (no sedation or stable neurologic patient).

Exclusion

  • Diaphragmatic paralysis (detected by ultrasonography).Patients\&Methods. 6
  • Pregnant women.
  • Age: \>= 18 years.
  • Surgical dressings over measurement point which would preclude ultrasound exam.
  • Underweight patients (Body mass index \<18.5 kg/m2).
  • Morbidly obese patient (Body mass index ≥ 40 kg/m2).
  • Primary neuro-muscular diseases.
  • Central coditions with depressed central respiratory drive (encephalitis, and brainstem haemorrhage/ischaemia).
  • Repiratory conditions with reduced pulmonary compliance (interstitial lung disease, pulmonary hemorrhage, and diffuse pulmonary infiltrates) or reduced chest wall compliance (kyphoscoliosis).
  • Cardiac conditions with high risk of weaning induced pulmonary edema (congestive heart failure, cyanotic heart diease, pulmonary hypertension, and ischemic heart diease).
  • Addict patients.
  • Patients with psychiatric disease.

Key Trial Info

Start Date :

June 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

April 1 2021

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04779463

Start Date

June 1 2020

End Date

April 1 2021

Last Update

March 3 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Faculty of Medicine - Menoufia University

Shibīn al Kawm, Menoufia, Egypt, 32511